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Lead exposure induces dysfunction of the cyclic guanosine
monophosphate-dependent vasodilator system through
downregulation of soluble guanylate cyclase (sGC)
expression. The endothelium not only releases vasodilators
but also vasoconstrictors such as endothelin-1 (ET-1). Our aim
was to explore the role of the vascular endothelium and ET-1
as possible mediators of lead-induced downregulation of
sGC. Isolated aortic segments from Wistar Kyoto rats were
incubated in the presence or absence of lead (1 parts per
million) for 24 h. Endothelium was mechanically removed in
some of the aorta segments. As reported previously, lead
exposure induced downregulation of sGC protein expression
in the intact aortic segments. However, lead exposure failed
to significantly modify sGC-b1 subunit expression in the
endothelium-denuded aortic segments. Incubation with a
selective ETA-type receptor inhibitor, BQ-123 (10
6 mol/l),
restored sGC protein expression in lead-exposed intact
aortic segments. As it has also been previously observed,
incubation in lead-containing medium resulted in the
upregulation of cyclooxygenase-2 (COX-2) in the intact aortic
segments. Denudation of endothelium partially abrogated
this effect of lead. Incubation with BQ-123 prevented the
lead-induced upregulation COX-2 in the intact aortic
segments. However, neither ET-1 content nor ETA-type
receptor expression were modified by lead exposure of
the aortic segments. As conclusion, the endothelium
through the activation of ETA-type receptors mediates
the downregulation of sGC expression by lead in the
vascular wall.
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Continuous exposure to low levels of lead is a well-known
cause of arterial hypertension in humans and in experimental
animals.1,2 However, the mechanisms involved in lead-
induced hypertension are not fully understood. Several
alterations in the nitric oxide (NO)-dependent vasodilator
system have been implicated in the pathogenesis of lead-
induced hypertension.3 Recently, we have described that lead
not only affects the endothelial function but also the smooth
muscle cells function.4 In fact, lead exposure was shown to
reduce the expression of the soluble guanylate cyclase (sGC)
in the vascular wall. This effect was independent of lead-
induced hypertension since in vitro incubation of isolated rat
aortic segments with lead also promoted downregulation of
sGC expression.5
sGC is the enzyme that is involved in the NO-induced
vasodilatation by catalyzing the formation of cyclic guanosine
monophosphate (cGMP) from guanine 50-triphosphate in
the smooth muscle cells.6 sGC is a heterodimer composed of
large (a1) and small (b1) subunits.
7 It is of note that the
presence of both subunits of sGC is required for NO to exert
its vasodilatory action.8 Although the intracellular signal
regulators of sGC expression are not yet completely
elucidated, different studies have demonstrated that cyclic
adenosine monophosphate-stimulating agents, such as prostag-
landins, downregulates sGC expression.9 In this regard, lead
has been shown to not only reduce the expression of sGC
but also induce the expression of the cyclooxygenase-2
(COX-2). Moreover, the blockade of COX-2 activity has
been shown to prevent the effect of lead on the sGC
expression.5 These observations point to the involvement of
COX-2 as the mediator of the lead-induced downregulation
of sGC.
Vascular endothelium plays a pivotal role in the main-
tenance of vascular tone by the release of several vasoactive
substances. The presence and the absence of endothelium
have been demonstrated to modify the level of different
proteins in the vascular wall.10,11 The endothelium not only
releases vasodilators such as NO but also vasoconstrictor
factors such as endothelin-1 (ET-1).12 ET-1 exerts its
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vasoconstrictor effects via activation of ETA-type receptors
located on the vascular smooth muscle layer.13
Several authors have shown that ET-1 is not only a potent
vasoconstrictor but also possess proinflammatory properties.
Interestingly, similar to lead, ET-1 induces COX-2 expression
in glomerular mesangial cells, myocardium and circulating
leukocytes.14,15 However, it is not clear if the endothelium
and particularly ET-1 may be involved in the effect of lead on
sGC and COX-2 expressions in the vascular wall. Therefore,
the aim of the present study was to determine the role of the
endothelium and ET-1 in the genesis of lead-induced
alteration of sGC expression in the blood vessel wall.
RESULTS
Involvement of the endothelium and ET-1 in sGC-b1 subunit
expression
As we have reported previously,5 in vitro incubation of intact
aortic segments with lead significantly decreased sGC-b1
subunit expression (Figure 1). However, lead exposure of de-
endothelialized aortic rings failed to significantly modify
sGC-b1 subunit expression (Figure 1). The absence of
endothelium, per se, did not change the sGC-b1 subunit
expression when the aortic rings were not exposed to lead
(Figure 1). No changes in b-actin expression were observed in
either intact or de-endothelialized aortic rings after incuba-
tion in either control or lead-containing media, thus
supporting the specificity of the above-mentioned changes
in sGC-b1 subunit expression (Figure 1).
Since the presence of endothelium seems to be pivotal for
lead-induced downregulation of sGC-b1 subunit expression,
we sought to determine whether ET-1 (one of the main
vasoactive mediators released by the endothelium) may be
involved. Addition of a specific ETA-type receptor antagonist,
BQ-123 (106 mol/l), to the intact aortic rings partially
reversed the lead-induced downregulation of sGC-b1 subunit
(Figure 2). BQ-123 (106 mol/l), by itself, failed to modify
sGC-b1 subunit expression in the aortic segments incubated
in the lead-free medium (Figures 1 and 2).
Relationship between ET-1 and COX-2 expression in
lead-exposed aortic segments
As we have demonstrated previously,5 the exposure of intact
aortic segments to lead stimulated COX-2 expression
(Figure 3). However, in de-endothelized aortic rings, lead
exposure failed to modify COX-2 expression (Figure 3).
There was no modification in the level of COX-2 expression
in the control de-endothelialized aortic rings compared with
the control intact aortic ings (Figure 3). BQ-123 (106 mol/l)
partially prevented the upregulation of COX-2 by lead in
intact aortic segments (Figure 4). BQ-123 (106 mol/l) failed
to modify COX-2 expression in aortic segments incubated in
lead-free medium (Figures 3 and 4).
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Figure 1 | Representative Western blot showing the expression of
the sGC-b1 subunit in endothelialized (þ End) and de-endothe-
lialized (End) aortic rings of control (C) and 1 p.p.m. lead-
incubated (Lead) aortic segments. The bottom blot shows the
expression of the constitutive protein b-actin. The bar graph
represents the densitometric values in arbitrary units (AU). Results are
presented as mean7s.e.m. of five different segments. *Po0.05,
versus control.
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Figure 2 | Representative Western blot showing the expression
of the sGC-b1 subunit in intact aortic rings incubated with the
selective ETA receptor inhibitor BQ-123 (10
6 mol/l) with or
without 1 p.p.m. of lead acetate. The bottom blot shows the
expression of the constitutive protein b-actin. Bar graph represents
the densitometric values in arbitrary units. Results are presented as
mean7s.e.m. of five different aortic segments. *Po0.05, versus
control.
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Figure 3 | Bar graph showing the expression of COX-2 protein in
endothelialized (þ End) and de-endothelialized (End) aortic
rings of control (C) and 1 p.p.m. lead-incubated (Lead) aortic
segments rats. Results are presented as mean7s.e.m. of five
different aortic segments. *Po0.05 versus endothelialized control.
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Despite the fact that BQ-123 prevented both down-
regulation of sGC and upregulation of COX-2 isoform
induced by lead in the intact aortic segments, the content of
ET-1 in the vascular wall was not modified by lead exposure
(Figure 5).
Expression of ETA-type receptor in lead-exposed aortic
segments
Exposure of intact aortic segments to lead did not modify the
level of expression of the ETA-type receptor (Figure 6). De-
endothelization of the aortic segments, per se, did not change
the expression of ETA-type receptor as compared to that
observed in the intact aortic segments (Figure 6). Moreover,
exposure of de-endothelized aortic segments to lead tended
to slightly reduced ETA-type receptor, although the difference
did not reach statistical significance (Figure 6).
DISCUSSION
The main finding of this study was the demonstration of
involvement of the endothelium and ET-1 as mediator of the
lead-induced downregulation of sGC in the vascular wall.
As described in a recent review,16 numerous mechanisms
have been implicated in the pathogenesis of lead-induced
hypertension. Chief among them is oxidative stress and
altered NO pathway, which has been the subject of several
investigations during the past decade.3–5,17–21 In this regard, it
has been demonstrated that lead exposure reduces the
availability of the endothelial-derived NO, mainly as a result
of NO inactivation by reactive oxygen species.17,19,20 In
addition, we have recently demonstrated that independently
of the effect of lead on the NO-generating system, lead
exposure downregulates sGC, the main receptor of NO in the
vascular wall.4,5
Khalil-Manesh et al.21 were among the first to show that
lead-induced hypertension in rats is associated with sig-
nificant reductions of plasma concentration and urinary
excretion of cGMP. In a subsequent study,22 they showed a
significant rise in cGMP levels in rats with lead-induced
hypertension treated with the chelating agent, dimercapto-
succinic acid, which possesses potent antioxidant properties.
Based on these observations, they theorized that lead-induced
hypertension may be due to the inactivation of endothelium-
derived relaxing factor. In a later study, Gonick et al.18
documented the occurrence of oxidative stress and compen-
satory upregulation of NO synthases in rats with lead-
induced hypertension. It is of note that while mean values for
plasma concentration and urinary excretion of cGMP were
less than the corresponding values found in their control
animals, the differences did not reach statistical significance.
Moreover, plasma and urine levels of total NO3
 and NO2

(NOx) measured during the established phase of hyper-
tension were comparable among rats with lead-induced
hypertension and the control animals. In a separate study,17
these investigators monitored urinary excretion of NOx in
rats with lead-induced hypertension exposed to lead for 12
weeks. They found a dramatic decline in urinary NOx
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Figure 4 | Representative Western blot showing the expression of
COX-2 protein in endothelized aortic rings incubated with and
without 1 p.p.m. lead in the presence of the selective ETA
receptor inhibitor BQ-123 (106 mol/l). The bar graph represents
the densitometric values in arbitrary units. Results are presented as
mean7s.e.m. of five different aortic segments. *Po0.05, versus
control.
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Figure 5 | Representative Western blot showing the expression of
ET-1 protein in intact aortic segments of control (C) and 1 p.p.m.
lead-incubated (Lead) aortic segments. The bottom shows the
expression of the constitutive protein b-actin. Bar graph represents
the densitometric values in arbitrary units. Results are presented as
mean7s.e.m. of five different aortic segments.
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Figure 6 | Representative Western blot showing the expression of
ETA-type receptor in endothelialized and de-endothelialized rat
aortic segments incubated with or without 1 p.p.m. lead. Bar
graph represents the densitometric values in arbitrary unit. Results
are mean7s.e.m. of four different aortic segments.
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excretion followed by a gradual rise to the control levels
during the maintenance phase of hypertension. The resto-
ration of plasma and urinary NOx in this model occurred
despite persistent NO inactivation by reactive oxygen species
as evidenced by overabundance of nitrotyrosine in various
tissues in these animals.19 It should be noted that the
normality of plasma concentration or urinary excretion of
the end products of NO metabolism (i.e. total NO3
þNO2)
is not necessarily indicative of the normality of biologically
active NO, especially when oxidative stress is present. This is
because nearly all of the NO produced in the body is
eventually converted to NO3 and NO2 irrespective of having
served its biological action or being intercepted and
inactivated by reactive oxygen species. For instance, the
primary and secondary by-products of NO interaction with
reactive oxygen species are either rapidly converted to NO3

and NO2
 via isomerization (ONOO-NO3) and degrada-
tion (ONOOH-OHþNO2) or at a later stage via turnover
of the nitrated molecules. Thus, caution should be exercised in
the interpretation of the plasma and urinary NO2þNO3 in the
assessment of the bioavailability of NO. Similarly, measure-
ments of plasma and urinary cGMP do not exclusively
represent the biological action of NO. This is because cGMP
level is a function of its production, which is regulated not only
by NO but also by natriuretic peptides as well as its
degradation by phosphodiesterases. These factors can vary
independently to affect cGMP levels in the intact animals.
However, some of these variabilities are reduced by the in vitro
experiments using isolated tissues such as those employed here.
Modification in the sGC expression has been found in the
vascular wall of aging rats, experimental model of myocardial
infarction and hypertension as well as during pulmonary
maturation.23–26 Indeed, several factors have been shown to
modulate sGC expression including cyclic adenosine mono-
phosphate, nerve growth factor and interleukin-1b.9,27
In a recent study, lead exposure was shown to raise
production of reactive oxygen species in both cultured
endothelial and smooth muscle cells, suggesting that altera-
tion of both endothelial and vascular smooth muscle cells
may contribute to the deleterious effect of lead on the
vascular wall.28 However, to our knowledge, it is not known
whether downregulation of sGC by lead is an endothelium-
mediated effect and/or it is related to a direct effect of lead on
the smooth muscle layer. The present study revealed that the
lead-induced downregulation of sGC-b1 subunit is signifi-
cantly reduced in the absence of endothelium, suggesting the
major involvement of endothelium in this phenomenon.
ET-1 is an endogenous vasoconstrictor released by the
endothelium. ET-1 exerts its effects on the smooth muscle
cells by the activation of ETA-type receptors. Several reports
have implicated the role of ET-1 in endothelial dysfunc-
tion.29,30 Therefore, the question raised was whether ET-1
may be involved in the observed endothelial-dependent effect
of lead on sGC expression.
The lead-induced downregulation of sGC-b1 subunit
expression in the intact aorta segments was substantially
mitigated by the specific ETA-type receptor antagonist, BQ-
123. This finding points to the involvement of ET-1 in the
endothelial-dependent effect of lead on sGC expression.
In a previous work, we demonstrated that lead exposure
stimulated the expression of the COX-2 isoform in the
vascular wall.5 Moreover, upregulation of COX-2 isoform by
lead was associated with lead-induced downregulation of
sGC-b1 subunit.
5 Previous in vitro studies have suggested that
ET-1, not only is a potent vasoconstrictor but it also has
proinflammatory properties. Indeed, ET-1 induces leukocyte
adhesion to cultured endothelial cells and stimulates release
of cytokines from isolated leukocytes.31–33 Moreover, in vivo
infusion of ET-1 stimulates the expression of COX-2 in the
myocardium and circulating leukocytes obtained from
guinea-pigs.15 Therefore, we sought to determine if the
endothelium and ET-1 are also involved in the stimulation of
COX-2 expression by lead. The denudation of endothelium
and the blockade of ETA-type receptor by BQ-123 partially
prevented the upregulation of COX-2 isoform by lead in the
vascular wall. These findings point to the role of endothelium
in lead-induced upregulation of COX-2 in vascular tissue by a
mechanism, which may involve ET-1.
The next step was to determine if the tissue content of ET-1
is modified by lead exposure in intact aortic rings. We found
no differences in the content of ET-1 between control and
lead-exposed intact aortic rings. This finding suggested that
the ET-1-mediated downregulation of sGC-b1 subunit by
lead did not depend on quantitative changes of ET-1
production by the endothelium. This observation is con-
cordant with an earlier in vivo study, which reported that
plasma ET-1 level was unaffected by the administration of
lead to rats.21 Since the ETA-type receptor antagonist, BQ-
123, prevented both lead-induced downregulation of sGC-b1
subunit and upregulation of COX-2, it is logical to assume
that lead must exert these actions by mechanisms that act at
the level of ETA receptor. In this regard, Daswood et al.
34 have
previously demonstrated that balloon angioplasty of pig
coronary arteries, a process that induces de-endothelialization,
increased ETA-type receptor expression. However, in our study,
the expression of ETA receptor was not modified by either de-
endothelization or lead exposure. Therefore, the BQ-123-
inhibitable effect of lead on the expression of sGC-b1 subunit
and COX-2 should occur downstream of ETA-type receptor.
Further studies are required to address this issue.
In conclusion, through the activation of the ETA-type
receptors, the endothelium plays a major role in the lead-
induced downregulation of sGC-b1 subunit and upregulation
of COX-2 in the rat vascular wall. These phenomena may be
involved, at least in part, in the vascular dysfunctionality
associated with lead-induced hypertension.
MATERIALS AND METHODS
Incubation of isolated aortic segment
Studies were approved by the Institutional Ethics Committee for
animals and were performed in accordance with the international
convention on animal experimentation. The experiments were
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carried out on male Wistar rats with average body weight of 300 g.
The animals were anesthetized with pentobarbital (30 mg/kg
intramuscularly) and exanguinated. The remaining blood was
removed by perfusing the aorta with 100 ml of isotonic saline. The
descending thoracic aorta was removed and cut into 5-mm-long
segments and individually suspended in culture solution (RPMI
(Roswell Park Memorial Institute) medium containing 5% fetal calf
serum, at 371C). In a subset of tissues, the endothelium was
mechanically eliminated by gentle rubbing. Using hematoxylin and
eosin staining, we verified the complete endothelial denudation. As
described previously,5 aortic segments were cut into three portions
and were then preincubated in RPMI medium containing 5% red
phenol-free fetal calf serum, 5 mmol/l glutamine, 2 105 U/l
penicillin and 3 105mg/l streptomycin for 1 h. Afterwards,
the medium was removed and replaced with fresh RPMI med-
ium containing 5% fetal calf serum. The aortic segments were
then incubated in the absence and in the presence of lead acetate
(1 parts per million (p.p.m.)) for 24 h. The dose of lead acetate
chosen was based on a previous study in which we observed that
1 p.p.m. lead induced a maximal reduction in sGC-b1 subunit
abundance.5 In a subset of tissues, ETA receptor inhibitor, BQ-123
(106 mol/l), was added to the culture solution. After the con-
clusion of the incubation period, the aortic segments were immedia-
tely frozen in liquid nitrogen and processed for molecular
biological determinations.
Determination of sGC-b1 subunit, COX-2 and ET-1 expression
by Western blot analysis
The expression of sGC-b1 subunit, COX-2, ET-1 and ETA-type
receptor were analyzed by Western blot as described elsewhere.23,24
In brief, the aortic rings were pulverized and solubilized in Laemmli
buffer containing 2-mercaptoethanol.35 The proteins obtained were
separated in denaturing sodium dodecyl sulfate/10% polyacrylamide
gels. Equal amount of proteins (20mg/lane) estimated by bicincho-
nic acid reagent (Pierce, Rockford, IL, USA) were loaded. The
proteins were then blotted into nitrocellulose (Immobilion-P,
Millipore Ibe´rica, S.A. Cerdanyola del Valle`s, Barcelona). The blots
were blocked overnight at 41C with 5% non-fat dry milk in Tris-
buffered saline with 0.1% Tween (20 mmol/l Tris-HCl, 137 mmol/l
NaCl, 0.1% Tween-20). Western blot analysis was developed with
antibodies against sGC-b1 subunit, COX-2 isoform, ET-1 and ETA-
type receptor. The blots were incubated with the first monoclonal
rabbit immunoglobulin G antibody sGC-b1 (1:2500) (Alexis
Biochem., Lausen, Switzerland), a monoclonal rabbit immunoglo-
bulin G antibody COX-2 (1:2500) (Alexis Biochem), a monoclonal
murine immunoglobulin G antibody ET-1 (1:500) (EMD Bios-
ciences, San Diego, CA, USA) and a polyclonal sheep immunoglo-
bulin G antibody (15 mg/ml) (Alexis Biochemical), respectively, for
1 h at room temperature and, after extensive washing, with the
second antibody (horseradish peroxidase-conjugated immunoglo-
bulin antibody) at a dilution of 1:1500 for another hour. Specific
sGC-b1 subunit, COX-2, ET-1 and ETA-type receptor proteins were
detected by enhanced chemoluminiscence (Amersham Corp, Frei-
burg, Germany) and evaluated by densitometry (Quantity One;
Biorad, Hercules, CA, USA). Prestained protein markers (Sigma)
were used for molecular mass determinations. To compare sGC-b1
subunit, COX-2, ET-1 and ETA-type receptor protein expression
with the expression of another constitutive protein, we analyzed the
expression of b-actin by Western blot, using a b-actin monoclonal
antibody (Sigma Aldrich, St Louis, MO, USA). For this purpose, a
parallel gel with identical samples was run and, after blotting onto
nitrocellulose, Western blot analysis was then performed with the b-
actin monoclonal antibody (1:2000).
Statistical analysis
Results are expressed as mean7s.e.m. To determine statistical
significance, the Mann–Whitney test was performed. A P-value
o0.05 was considered statistically significant.
ACKNOWLEDGMENTS
This work was supported by a grant from Fondo de Investigacio´n
Sanitaria de la Seguridad Social (FISS PI020347) and RED Heracles
(FISS G03/045). We thank Ruth Ferna´ndez for technical support and
Begon˜a Larrea for secretarial assistance.
REFERENCES
1. Sharp DS, Osterloh J, Becker CE et al. Blood pressure and blood
lead concentration in bus drivers. Environ Health Perspect 1988; 78:
131–137.
2. Sharp DS, Becker CE, Smith AH. Chronic low-level lead exposure:
its role in the pathogenesis of hypertension. Med Toxicol 1987; 2:
210–232.
3. Vaziri ND, Ding Y, Ni Z. Nitric oxide synthase expression in the course of
lead-induced hypertension. Hypertension 1999; 34: 558–562.
4. Marques M, Milla´s I, Jime´nez A et al. Alteration of the soluble guanylate
cyclase system in the vascular wall of lead-induced hypertension in rats.
J Am Soc Nephrol 2001; 12: 2594–2600.
5. Courtois E, Marques M, Barrientos A et al. Lead-induced downregulation
of soluble guanylate cyclase in isolated rat aortic segments mediated by
reactive oxygen species and cyclooxigenase-2. J Am Soc Nephrol 2003; 14:
1464–1470.
6. Katsuki S, Arnold W, Mittal C, Murad F. Stimulation of guanylate cyclase
by sodium nitroprusside, nitroglycerine and nitric oxide in various tissue
preparations and comparison to the effects of sodium azyde and
hychoxylamine. J Cyclic Nucleotide Res 1977; 3: 23–35.
7. Gerzar R, Bohme E, Hoffman R, Shultz G. Soluble guanylate cyclase
purified from bovine lung contains heme copper. FEBS Lett 1981; 132:
71–74.
8. Buechler WA, Nekane M, Murad F. Expression of soluble guanylate cyclase
activity requires both enzyme subunits. Biochem Biophys Res Commun
1991; 174: 351–357.
9. Parapetropoulos A, Marczin N, Mora G et al. Regulation of vascular
smooth muscle soluble guanylate cyclase activity, mRNA and protein
levels by cAMP-elevating agents. Hypertension 1995; 26: 696–704.
10. Monto´n M, Lo´pez-Farre´ A, Mosquera JR et al. Endogenous angiotensin II
produced by endothelium regulates interleukin-1b-stimulated nitric
oxide generation in rat isolated vessels. Hypertension 1997; 30:
1191–1197.
11. Werba JP, Martinez V, Abulafia DP et al. Marked neointimal lipoprotein
lipase increase in distinct models of proclivity to atherosclerosis: a feature
independent of endothelial layer integrity. Atherosclerosis 2001; 156:
91–101.
12. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor
peptide produced by vascular endothelial cells. Nature 1998; 332:
411–415.
13. Russell FD, Skepper JN, Davenport AP. Detection of endothelin receptors
in human coronary artery vascular smooth muscle cells but not
endothelial cells by using electron microscope autoradiography.
Cardiovasc Pharmacol 1997; 29: 820–826.
14. Sugimoto T, Haneda M, Sawano H et al. Endothelin-1 induces
cyclooxygenase-2 expression via nuclear factor of activated T-cell
transcription factor in glomerular mesangial cells. J Am Soc Nephrol 2001;
12: 1359–1368.
15. Molero L, Farre´ J, Garcı´a-Mendez A et al. Endothelin-1 induced
proinflammatory markers in the myocardium and leukocytes of
guinea-pigs: role of glycoprotein IIB/IIIA receptors. Cardiovasc Res 2003;
57: 109–118.
16. Vaziri ND, Sica D. Lead-induced hypertension: role of oxidative stress. Curr
Hypertens Rep 2004; 6: 314–320.
17. Vaziri ND, Ding Y, Ni Z, Gonick HC. Altered nitric oxide metabolism and
increased oxygen free radical activity in lead-induced hypertension: effect
of lazaroid therapy. Kidney Int 1997; 52: 1042–1046.
Kidney International (2006) 69, 685–690 689
L Molero et al.: Role of endothelin-1 in lead-induced hypertension o r i g i n a l a r t i c l e
18. Gonick HC, Ding Y, Bondy SC et al. Lead-induced hypertension: interplay
of nitric oxide and reactive oxygen species. Hypertension 1997; 30:
1487–1492.
19. Vaziri ND, Liang K, Ding Y. Increased NO inactivation and sequestration in
lead-induced hypertension: Effect of vitamin E. Kidney Int 1999; 56:
1492–1498.
20. Vaziri ND, Ding Y, Ni Z. Compensatory upregulation of nitric oxide
synthase isoforms in lead-induced hypertension; reversal by a
superoxide dismutase-mimetic drug. J Pharmacol Exp Therap 2001; 298:
679–685.
21. Khalil-Manesh F, Gonick HC, Elmar WJ. Lead-induced hypertension:
possible role of endothelial factors. Am J Hypertens 1993; 6: 723–729.
22. Khalil-Manesh F, Gonick HC, Elmar WJ et al. Effect of chelation treatment
with dimercaptosuccinic acid (DMSA) on lead-related blood pressure
changes. Environ Res 1994; 65: 86–99.
23. Lo´pez-Farre´ A, Rodrı´guez-Feo JA, Garcı´a Colis E et al. Reduction of the
soluble cyclic GMP vasorelaxing system in the vascular wall of stroke
prone spontaneously hypertensive rats. Effect of the a1-receptor blocked
doxazosin. J Hypertens 2002; 20: 463–470.
24. Moreno L, Gonzalez-Luis G, Cogolludo A et al. Soluble guanylyl cyclase
during postnatal porcine pulmonary maturation. Am J Physiol Lung Cell
Mol Physiol 2005; 288: L125–L130.
25. Bauersachs J, Bouloumie A, Mulsch A et al. Vasodilator dysfunction in
aged spontaneously hypertensive rats: changes in NO synthase III and
soluble guanylyl cyclase expression and in superoxide anion production.
Cardiovasc Res 1998; 37: 772–779.
26. Bauersachs J, Bouloumie A, Fraccarollo D et al. Endothelial dysfunction in
chronic myocardial infarction despite increased vascular endothelial nitric
oxide synthase and soluble guanylate cyclase expression: role of
enhanced vascular superoxide anion production. Circulation 1999; 100:
292–298.
27. Liu H, Force T, Bloch KD. Nerve growth factor decreases soluble guanylate
cyclase in rat PC12 cells. J Biol Chem 1997; 272: 6038–6043.
28. Ni Z, Hou S, Barton CH, Vaziri ND. Lead exposure raises superoxide and
hydrogen peroxide in human endothelial and vascular smooth muscle
cells. Kidney Int 2004; 6: 2329–2336.
29. Nohria A, Garrett L, Johnson W et al. Endothelin-1 and vascular tone in
subjects with atherogenic risk factors. Hypertension 2003; 42: 43–48.
30. Amiri F, Virdis A, Neves MF et al. Endothelium-restricted overexpression
of human endothelin-1 causes vascular remodeling and endothelial
dysfunction. Circulation 2004; 110: 2233–2240.
31. Lo´pez-Farre´ A, Riesco A, Espinosa G et al. Effect of endothelin-1 on
neutrophil adhesion to endothelial cells and perfused heart. Circulation
1993; 88: 1166–1171.
32. McCarron RM, Wang L, Stanimirovic DB, Spatz M. Endothelin induction of
adhesion molecule expression on human brain microvascular endothelial
cells. Neurosci Lett 1993; 156: 31–34.
33. McMillen MA, Huribal M, Cunningham ME et al. Endothelin-1 increases
intracellular calcium in human monocytes and causes production of
interleukin-6. Crit Care Med 1995; 23: 34–40.
34. Dashwood MR, Noertersheuser P, Kirchengast M, Munter K. Altered
endothelin-1 binding following balloon angioplasty of pig coronary
arteries: effect of the ETA receptor antagonist, LU 135252. Cardiovasc Res
1999; 43: 445–456.
35. Laemmli NK. Change of structural proteins during the assembly of the
head of bacteriophage T4. Nature 1970; 227: 680–685.
690 Kidney International (2006) 69, 685–690
o r i g i n a l a r t i c l e L Molero et al.: Role of endothelin-1 in lead-induced hypertension
